# Glympse Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/glympse-bio

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.glympsebio.com
- Total disclosed funding: $52M
- Latest round: Series B (May 29, 2020)
- Investors on record: 15

## About

Glympse Bio, Inc. is a biotechnology company specializing in the development of innovative diagnostic solutions aimed at improving patient care through real-time insights into disease progression.Founded in 2015 and headquartered in Cambridge, US, Glympse Bio, Inc. focuses on delivering advanced diagnostic technologies. The company, led by founder Sangeeta Bhatia, has successfully raised USD 16 mn in Series A funding in April 2023, marking a significant milestone in their growth trajectory. The firm has engaged in 7 total deals to date, with a current company valuation of USD 46.96 mn.Glympse Bio offers a suite of diagnostics solutions designed to monitor disease progression through innovative biomarker technologies. Their primary target customers include healthcare providers and researchers interested in enhancing patient monitoring capabilities. The company's services are primarily marketed in North America and Europe, where there is a strong demand for advanced diagnostic tools.Glympse Bio's revenue model is centered around product sales and partnerships within the healthcare sector. The company generates income through the sale of diagnostic products, with additional revenue streams arising from collaborations with healthcare institutions and research organizations. This structural approach allows for a diverse range of income sources while promoting their innovative diagnostic technologies.Looking ahead, Glympse Bio plans to introduce new diagnostic products aimed at expanding their clinical applications by the end of 2024. The company is also targeting expansion into international markets in Asia and Europe to increase its market presence. The recent funding of USD 16 mn will be allocated towards research and development for these new products, as well as scaling operations to support market entry initiatives.

## Funding rounds

- Series B, May 29, 2020, $26M — ARCH Venture Partners, CRV, Temasek Holdings, Polaris Partners, New Leaf Venture Partners, Gilead Sciences, Inc., GreatPoint Ventures, Alumni Ventures Group, DNS Capital, Section 32, Catalio Capital Management
- Series A, Jul 20, 2018, $26M — ARCH Venture Partners, CRV, Polaris Partners, Gilead Sciences, Inc., GreatPoint Ventures, Yonghua Capital, Heritage Provider Network, Rivas Capital, Inevitable Ventures

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- CRV (https://capitalatlas.ai/funds/crv) — Series A, Series B
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B
- Gilead Sciences, Inc. — Series A, Series B
- GreatPoint Ventures (https://capitalatlas.ai/funds/greatpoint-ventures) — Series A, Series B
- Yonghua Capital (https://capitalatlas.ai/funds/yonghua-capital) — Series A
- Heritage Provider Network — Series A
- Rivas Capital — Series A
- Inevitable Ventures (https://capitalatlas.ai/funds/inevitable-ventures) — Series A
- Temasek Holdings — Series B
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series B
- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series B
- DNS Capital (https://capitalatlas.ai/funds/dns-capital) — Series B
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series B
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series B